Effectiveness and Safety of Risankizumab for Psoriasis in a Liver Transplant Patient With Recurrent Metastatic Hepatocellular Carcinoma.

Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy. We present a case of successful and well-tolerated treatment with RZB over an 18-month follow-up period in a patient with multiple comorbidities, including liver transplantation, recurrent hepatocellular carcinoma (HCC) with adrenal metastases, and severe chronic kidney disease.